Acute anti-obesity treatment with celastrol reduces body weight, cerebral inflammation and metabolic imbalances in mice.

backgroundThe global rise in obesity is predominantly driven by energy dense foods consumption and sedentary lifestyles that contribute to a growing burden of metabolic and neuroinflammatory comorbidities. Obesity is linked to a chronic low-grade inflammatory profile, as well as to a localized neuroendocrine imbalance and inflammatory response in the brain, including regions regulating energy homeostasis, reward and motivational centers. Anti-obesity medications that reduce body weight are being extensively used across the world, and the specific cerebral mechanisms underlying its action are yet to be clarified.

methodsWe investigated the cerebral and systemic effects inherent to obesity development and treatment with celastrol, an anti-obesity and anti-inflammatory agent, in a murine model of diet-induced obesity (DIO) using a multimodal approach. We characterized obesity progression and celastrol acute treatment by comparing body weight (BW), food intake, changes in brain microstructure by in vivo magnetic resonance imaging (MRI) and ex vivo by immunofluorescence (IF), investigated its metabolic rearrangements using

resultsOur findings indicate that obesity induces detectable neuroinflammation, evident through diffusion MRI alterations and increased glial activation, with quantifiable morphological changes. Treatment resulted in significant BW reduction, diffusion MRI signal changes, particularly in the hypothalamus, a decrease in glial activation, a regularization of cerebral osmolyte concentrations, decreased cellular proliferation and astrocytic metabolism markers, and anti-inflammatory cytokine changes.

conclusionsThese results support the role of celastrol as an anti-obesity treatment, with anti-inflammatory effects in the hypothalamus and associated cerebral metabolic rearrangements, and prove MRI techniques as valid tools to characterize its effects.